🚀 VC round data is live in beta, check it out!
Changchun High-Tech Valuation Multiples
Discover revenue and EBITDA valuation multiples for Changchun High-Tech and similar public comparables like Apellis Pharmaceuticals, Laboratorios Rovi, CR Pharmaceutical, Dong-E-E-Jiao and more.
Changchun High-Tech Overview
About Changchun High-Tech
Changchun High-Tech Industry (Group) Co Ltd is engaged in the production and sales of biopharmaceuticals, Chinese patent medicine production, and real estate development. The company operates its business through three segments. The Pharmaceuticals segment focuses on the research and development, manufacturing, and sales of genetically engineered biologics, human vaccines, traditional Chinese medicines, and chemical pharmaceuticals. The Real Estate segment is involved in property development and sales. The Services segment provides scientific research and technical support, along with leasing and various business-related services. It generates the majority of its revenue from the Pharmaceuticals segment.
Founded
1993
HQ
Employees
11.5K
Website
Sectors
Financials (FY)
EV
$5B
Changchun High-Tech Financials
Changchun High-Tech reported last fiscal year revenue of $2B and EBITDA of $557M.
In the same fiscal year, Changchun High-Tech generated $2B in gross profit, $557M in EBITDA, and $379M in net income.
Revenue (LTM)
Changchun High-Tech P&L
In the most recent fiscal year, Changchun High-Tech reported revenue of $2B and EBITDA of $557M.
Changchun High-Tech expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $2B | XXX | XXX | XXX |
| Gross Profit | — | XXX | $2B | XXX | XXX | XXX |
| Gross Margin | — | XXX | 86% | XXX | XXX | XXX |
| EBITDA | — | XXX | $557M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 28% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 27% | XXX | XXX | XXX |
| Net Profit | — | XXX | $379M | XXX | XXX | XXX |
| Net Margin | — | XXX | 19% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Changchun High-Tech Stock Performance
Changchun High-Tech has current market cap of $5B, and enterprise value of $5B.
Market Cap Evolution
Changchun High-Tech's stock price is $12.70.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5B | $5B | -0.8% | XXX | XXX | XXX | $0.93 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialChangchun High-Tech Valuation Multiples
Changchun High-Tech trades at 2.4x EV/Revenue multiple, and 8.7x EV/EBITDA.
EV / Revenue (LTM)
Changchun High-Tech Financial Valuation Multiples
As of April 18, 2026, Changchun High-Tech has market cap of $5B and EV of $5B.
Equity research analysts estimate Changchun High-Tech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Changchun High-Tech has a P/E ratio of 13.7x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5B | XXX | $5B | XXX | XXX | XXX |
| EV (current) | $5B | XXX | $5B | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 2.4x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 8.7x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 8.9x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 2.8x | XXX | XXX | XXX |
| P/E | — | XXX | 13.7x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 35.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Changchun High-Tech Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Changchun High-Tech Margins & Growth Rates
Changchun High-Tech's revenue in the last fiscal year declined by (8%).
Changchun High-Tech's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Changchun High-Tech Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (8%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 28% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (38%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 31% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 11% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 16% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 58% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Changchun High-Tech Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Changchun High-Tech | XXX | XXX | XXX | XXX | XXX | XXX |
| Apellis Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Laboratorios Rovi | XXX | XXX | XXX | XXX | XXX | XXX |
| CR Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Dong-E-E-Jiao | XXX | XXX | XXX | XXX | XXX | XXX |
| Dianthus Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Changchun High-Tech M&A Activity
Changchun High-Tech acquired XXX companies to date.
Last acquisition by Changchun High-Tech was on XXXXXXXX, XXXXX. Changchun High-Tech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Changchun High-Tech
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialChangchun High-Tech Investment Activity
Changchun High-Tech invested in XXX companies to date.
Changchun High-Tech made its latest investment on XXXXXXXX, XXXXX. Changchun High-Tech invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Changchun High-Tech
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Changchun High-Tech
| When was Changchun High-Tech founded? | Changchun High-Tech was founded in 1993. |
| Where is Changchun High-Tech headquartered? | Changchun High-Tech is headquartered in China. |
| How many employees does Changchun High-Tech have? | As of today, Changchun High-Tech has over 11K employees. |
| Is Changchun High-Tech publicly listed? | Yes, Changchun High-Tech is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Changchun High-Tech? | Changchun High-Tech trades under 000661 ticker. |
| When did Changchun High-Tech go public? | Changchun High-Tech went public in 1996. |
| Who are competitors of Changchun High-Tech? | Changchun High-Tech main competitors are Apellis Pharmaceuticals, Laboratorios Rovi, CR Pharmaceutical, Dong-E-E-Jiao. |
| What is the current market cap of Changchun High-Tech? | Changchun High-Tech's current market cap is $5B. |
| What is the current revenue of Changchun High-Tech? | Changchun High-Tech's last fiscal year revenue is $2B. |
| What is the current EV/Revenue multiple of Changchun High-Tech? | Current revenue multiple of Changchun High-Tech is 2.4x. |
| Is Changchun High-Tech profitable? | No, Changchun High-Tech is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.